Cargando…

Vaccine pharmacovigilance in India: Current context and future perspective

Pharmacovigilance of vaccines is of paramount importance to promote the safe use of vaccines among their recipients. India launched the Adverse Events Following Immunization (AEFI) surveillance program in 1986 for monitoring suspected adverse events following immunization and since then, the AEFI su...

Descripción completa

Detalles Bibliográficos
Autor principal: Meher, Bikash Ranjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759530/
https://www.ncbi.nlm.nih.gov/pubmed/31571710
http://dx.doi.org/10.4103/ijp.IJP_53_19
_version_ 1783453709290700800
author Meher, Bikash Ranjan
author_facet Meher, Bikash Ranjan
author_sort Meher, Bikash Ranjan
collection PubMed
description Pharmacovigilance of vaccines is of paramount importance to promote the safe use of vaccines among their recipients. India launched the Adverse Events Following Immunization (AEFI) surveillance program in 1986 for monitoring suspected adverse events following immunization and since then, the AEFI surveillance guideline has been updated periodically, with the latest being in 2015. The successful AEFI surveillance program in India required the concerted effort of all stakeholders such as National AEFI Secretariat, National Technical Collaborating Centre, Central Drug Standard Control Organization, marketing authorization holder, and health-care professionals.
format Online
Article
Text
id pubmed-6759530
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-67595302019-09-30 Vaccine pharmacovigilance in India: Current context and future perspective Meher, Bikash Ranjan Indian J Pharmacol Educational Forum Pharmacovigilance of vaccines is of paramount importance to promote the safe use of vaccines among their recipients. India launched the Adverse Events Following Immunization (AEFI) surveillance program in 1986 for monitoring suspected adverse events following immunization and since then, the AEFI surveillance guideline has been updated periodically, with the latest being in 2015. The successful AEFI surveillance program in India required the concerted effort of all stakeholders such as National AEFI Secretariat, National Technical Collaborating Centre, Central Drug Standard Control Organization, marketing authorization holder, and health-care professionals. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6759530/ /pubmed/31571710 http://dx.doi.org/10.4103/ijp.IJP_53_19 Text en Copyright: © 2019 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Educational Forum
Meher, Bikash Ranjan
Vaccine pharmacovigilance in India: Current context and future perspective
title Vaccine pharmacovigilance in India: Current context and future perspective
title_full Vaccine pharmacovigilance in India: Current context and future perspective
title_fullStr Vaccine pharmacovigilance in India: Current context and future perspective
title_full_unstemmed Vaccine pharmacovigilance in India: Current context and future perspective
title_short Vaccine pharmacovigilance in India: Current context and future perspective
title_sort vaccine pharmacovigilance in india: current context and future perspective
topic Educational Forum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759530/
https://www.ncbi.nlm.nih.gov/pubmed/31571710
http://dx.doi.org/10.4103/ijp.IJP_53_19
work_keys_str_mv AT meherbikashranjan vaccinepharmacovigilanceinindiacurrentcontextandfutureperspective